Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 14 entries
Sorted by: Best Match Show Resources per page
Severe ocular pain after anti-VEGF intravitreal injection.

Enfermedades infecciosas y microbiologia clinica (English ed.)

Tabuenca Del Barrio L, Mozo Cuadrado M, Compains Silva E, Plaza Ramos P.
PMID: 31353187
Enferm Infecc Microbiol Clin (Engl Ed). 2020 Feb;38(2):86-87. doi: 10.1016/j.eimc.2019.07.002. Epub 2019 Jul 26.

No abstract available.

Cite
Tabuenca Del Barrio L, Mozo Cuadrado M, Compains Silva E, et al. Severe ocular pain after anti-VEGF intravitreal injection. Enferm Infecc Microbiol Clin (Engl Ed). 2019;38(2):86-87doi: 10.1016/j.eimc.2019.07.002.
Tabuenca Del Barrio, L., Mozo Cuadrado, M., Compains Silva, E., & Plaza Ramos, P. (2020). Severe ocular pain after anti-VEGF intravitreal injection. Enfermedades infecciosas y microbiologia clinica (English ed.), 38(2), 86-87. https://doi.org/10.1016/j.eimc.2019.07.002
Tabuenca Del Barrio, Laura, et al. "Severe ocular pain after anti-VEGF intravitreal injection." Enfermedades infecciosas y microbiologia clinica (English ed.) vol. 38,2 (2020): 86-87. doi: https://doi.org/10.1016/j.eimc.2019.07.002
Tabuenca Del Barrio L, Mozo Cuadrado M, Compains Silva E, Plaza Ramos P. Severe ocular pain after anti-VEGF intravitreal injection. Enferm Infecc Microbiol Clin (Engl Ed). 2020 Feb;38(2):86-87. doi: 10.1016/j.eimc.2019.07.002. Epub 2019 Jul 26. Spanish. PMID: 31353187.
Copy Download .nbib Format: NLM
Financial toxicity and cancer treatments: Help from biosimilars - The explanatory case of bevacizumab.

European journal of cancer (Oxford, England : 1990)

Giuliani J, Fiorica F, Albanese V, Bonetti A.
PMID: 33278773
Eur J Cancer. 2021 Jan;143:40-42. doi: 10.1016/j.ejca.2020.11.004. Epub 2020 Dec 02.

No abstract available.

Cite
Giuliani J, Fiorica F, Albanese V, et al. Financial toxicity and cancer treatments: Help from biosimilars - The explanatory case of bevacizumab. Eur J Cancer. 2020;143:40-42doi: 10.1016/j.ejca.2020.11.004.
Giuliani, J., Fiorica, F., Albanese, V., & Bonetti, A. (2021). Financial toxicity and cancer treatments: Help from biosimilars - The explanatory case of bevacizumab. European journal of cancer (Oxford, England : 1990), 14340-42. https://doi.org/10.1016/j.ejca.2020.11.004
Giuliani, Jacopo, et al. "Financial toxicity and cancer treatments: Help from biosimilars - The explanatory case of bevacizumab." European journal of cancer (Oxford, England : 1990) vol. 143 (2021): 40-42. doi: https://doi.org/10.1016/j.ejca.2020.11.004
Giuliani J, Fiorica F, Albanese V, Bonetti A. Financial toxicity and cancer treatments: Help from biosimilars - The explanatory case of bevacizumab. Eur J Cancer. 2021 Jan;143:40-42. doi: 10.1016/j.ejca.2020.11.004. Epub 2020 Dec 02. PMID: 33278773.
Copy Download .nbib Format: NLM
Commentary: Single-use bevacizumab: The final solution?.

Indian journal of ophthalmology

Narayanan R.
PMID: 32461440
Indian J Ophthalmol. 2020 Jun;68(6):1102. doi: 10.4103/ijo.IJO_24_20.

No abstract available.

Cite
Narayanan R. Commentary: Single-use bevacizumab: The final solution?. Indian J Ophthalmol. 2020;68(6):1102doi: 10.4103/ijo.IJO_24_20.
Narayanan, R. (2020). Commentary: Single-use bevacizumab: The final solution?. Indian journal of ophthalmology, 68(6), 1102. https://doi.org/10.4103/ijo.IJO_24_20
Narayanan, Raja. "Commentary: Single-use bevacizumab: The final solution?." Indian journal of ophthalmology vol. 68,6 (2020): 1102. doi: https://doi.org/10.4103/ijo.IJO_24_20
Narayanan R. Commentary: Single-use bevacizumab: The final solution?. Indian J Ophthalmol. 2020 Jun;68(6):1102. doi: 10.4103/ijo.IJO_24_20. PMID: 32461440; PMCID: PMC7508092.
Copy Download .nbib Format: NLM
In Reply.

The oncologist

Papachristos A, Kemos P, Kalofonos H, Sivolapenko G.
PMID: 33044037
Oncologist. 2020 Dec;25(12):e2023. doi: 10.1002/onco.13565. Epub 2020 Oct 26.

No abstract available.

Cite
Papachristos A, Kemos P, Kalofonos H, et al. In Reply. Oncologist. 2020;25(12):e2023doi: 10.1002/onco.13565.
Papachristos, A., Kemos, P., Kalofonos, H., & Sivolapenko, G. (2020). In Reply. The oncologist, 25(12), e2023. https://doi.org/10.1002/onco.13565
Papachristos, Apostolos, et al. "In Reply." The oncologist vol. 25,12 (2020): e2023. doi: https://doi.org/10.1002/onco.13565
Papachristos A, Kemos P, Kalofonos H, Sivolapenko G. In Reply. Oncologist. 2020 Dec;25(12):e2023. doi: 10.1002/onco.13565. Epub 2020 Oct 26. PMID: 33044037; PMCID: PMC8108043.
Copy Download .nbib Format: NLM
Bevacizumab Maintenance in Metastatic Colorectal Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Mo M, Yang J, Zhu X, Zhu J.
PMID: 29863975
J Clin Oncol. 2018 Aug 10;36(23):2451-2452. doi: 10.1200/JCO.2018.78.3795. Epub 2018 Jun 04.

No abstract available.

Cite
Mo M, Yang J, Zhu X, et al. Bevacizumab Maintenance in Metastatic Colorectal Cancer. J Clin Oncol. 2018;36(23):2451-2452doi: 10.1200/JCO.2018.78.3795.
Mo, M., Yang, J., Zhu, X., & Zhu, J. (2018). Bevacizumab Maintenance in Metastatic Colorectal Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36(23), 2451-2452. https://doi.org/10.1200/JCO.2018.78.3795
Mo, Miao, et al. "Bevacizumab Maintenance in Metastatic Colorectal Cancer." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 36,23 (2018): 2451-2452. doi: https://doi.org/10.1200/JCO.2018.78.3795
Mo M, Yang J, Zhu X, Zhu J. Bevacizumab Maintenance in Metastatic Colorectal Cancer. J Clin Oncol. 2018 Aug 10;36(23):2451-2452. doi: 10.1200/JCO.2018.78.3795. Epub 2018 Jun 04. PMID: 29863975.
Copy Download .nbib Format: NLM
Physician Networks and the Complex Contagion of Clinical Treatment.

JAMA network open

Centola D.
PMID: 31899525
JAMA Netw Open. 2020 Jan 03;3(1):e1918585. doi: 10.1001/jamanetworkopen.2019.18585.

No abstract available.

Cite
Centola D. Physician Networks and the Complex Contagion of Clinical Treatment. JAMA Netw Open. 2020;3(1):e1918585doi: 10.1001/jamanetworkopen.2019.18585.
Centola, D. (2020). Physician Networks and the Complex Contagion of Clinical Treatment. JAMA network open, 3(1), e1918585. https://doi.org/10.1001/jamanetworkopen.2019.18585
Centola, Damon. "Physician Networks and the Complex Contagion of Clinical Treatment." JAMA network open vol. 3,1 (2020): e1918585. doi: https://doi.org/10.1001/jamanetworkopen.2019.18585
Centola D. Physician Networks and the Complex Contagion of Clinical Treatment. JAMA Netw Open. 2020 Jan 03;3(1):e1918585. doi: 10.1001/jamanetworkopen.2019.18585. PMID: 31899525.
Copy Download .nbib Format: NLM
Formulation of nanoliposome-encapsulated bevacizumab (Avastin): Statistical optimization for enhanced drug encapsulation and properties evaluation.

International journal of pharmaceutics

Malakouti-Nejad M, Bardania H, Aliakbari F, Baradaran-Rafii A, Elahi E, Monti D, Morshedi D.
PMID: 32956821
Int J Pharm. 2020 Nov 30;590:119895. doi: 10.1016/j.ijpharm.2020.119895. Epub 2020 Sep 19.

Bevacizumab (Avastin®), an anti-vascular endothelial growth factor, is one of the most effective drugs widely used to inhibit ocular angiogenesis. Nanoliposomes were recruited to improve the accessibility of bevacizumab (BVZ) during treatment. To optimize drug entrapment efficiency (DEE %),...

Cite
Malakouti-Nejad M, Bardania H, Aliakbari F, et al. Formulation of nanoliposome-encapsulated bevacizumab (Avastin): Statistical optimization for enhanced drug encapsulation and properties evaluation. Int J Pharm. 2020;590:119895doi: 10.1016/j.ijpharm.2020.119895.
Malakouti-Nejad, M., Bardania, H., Aliakbari, F., Baradaran-Rafii, A., Elahi, E., Monti, D., & Morshedi, D. (2020). Formulation of nanoliposome-encapsulated bevacizumab (Avastin): Statistical optimization for enhanced drug encapsulation and properties evaluation. International journal of pharmaceutics, 590119895. https://doi.org/10.1016/j.ijpharm.2020.119895
Malakouti-Nejad, Maryam, et al. "Formulation of nanoliposome-encapsulated bevacizumab (Avastin): Statistical optimization for enhanced drug encapsulation and properties evaluation." International journal of pharmaceutics vol. 590 (2020): 119895. doi: https://doi.org/10.1016/j.ijpharm.2020.119895
Malakouti-Nejad M, Bardania H, Aliakbari F, Baradaran-Rafii A, Elahi E, Monti D, Morshedi D. Formulation of nanoliposome-encapsulated bevacizumab (Avastin): Statistical optimization for enhanced drug encapsulation and properties evaluation. Int J Pharm. 2020 Nov 30;590:119895. doi: 10.1016/j.ijpharm.2020.119895. Epub 2020 Sep 19. PMID: 32956821.
Copy Download .nbib Format: NLM
In situ dsDNA-bevacizumab anticancer monoclonal antibody interaction electrochemical evaluation.

Analytica chimica acta

Tomé LI, Marques NV, Diculescu VC, Oliveira-Brett AM.
PMID: 26526907
Anal Chim Acta. 2015 Oct 22;898:28-33. doi: 10.1016/j.aca.2015.09.049. Epub 2015 Oct 08.

The interaction of the anticancer monoclonal antibody bevacizumab (BEVA) with double-stranded DNA (dsDNA) was studied by voltammetry and gel-electrophoresis in incubated samples and using the dsDNA-electrochemical biosensor. The voltammetric results revealed a decrease and disappearance of the dsDNA oxidation...

Cite
Tomé LI, Marques NV, Diculescu VC, et al. In situ dsDNA-bevacizumab anticancer monoclonal antibody interaction electrochemical evaluation. Anal Chim Acta. 2015;898:28-33doi: 10.1016/j.aca.2015.09.049.
Tomé, L. I., Marques, N. V., Diculescu, V. C., & Oliveira-Brett, A. M. (2015). In situ dsDNA-bevacizumab anticancer monoclonal antibody interaction electrochemical evaluation. Analytica chimica acta, 89828-33. https://doi.org/10.1016/j.aca.2015.09.049
Tomé, Luciana I N, et al. "In situ dsDNA-bevacizumab anticancer monoclonal antibody interaction electrochemical evaluation." Analytica chimica acta vol. 898 (2015): 28-33. doi: https://doi.org/10.1016/j.aca.2015.09.049
Tomé LI, Marques NV, Diculescu VC, Oliveira-Brett AM. In situ dsDNA-bevacizumab anticancer monoclonal antibody interaction electrochemical evaluation. Anal Chim Acta. 2015 Oct 22;898:28-33. doi: 10.1016/j.aca.2015.09.049. Epub 2015 Oct 08. PMID: 26526907.
Copy Download .nbib Format: NLM
[Authentication study of the preparation 'Avastin' by means of chemical-toxicological analysis].

Sudebno-meditsinskaia ekspertiza

Mesonzhnik NV, Kuznetsov RM, Postnikov PV, Bochkareva NL, Markin PA, Kurynina KO, Appolonova SA.
PMID: 31626195
Sud Med Ekspert. 2019;62(5):47-53. doi: 10.17116/sudmed20196205147.

Falsification and use of low-quality drugs of biological origin creates a threat to public health. To a greater extent, costly drugs, including bevacizumab, are exposed to similar abuses. Timely determination of cases of forgery or the improper clinical use...

Cite
Mesonzhnik NV, Kuznetsov RM, Postnikov PV, et al. Issledovanie podlinnosti preparata 'Avastin' metodami khimiko-toksikologicheskogo analiza. [Authentication study of the preparation 'Avastin' by means of chemical-toxicological analysis]. Sud Med Ekspert. 2019;62(5):47-53doi: 10.17116/sudmed20196205147.
Mesonzhnik, N. V., Kuznetsov, R. M., Postnikov, P. V., Bochkareva, N. L., Markin, P. A., Kurynina, K. O., & Appolonova, S. A. (2019). Issledovanie podlinnosti preparata 'Avastin' metodami khimiko-toksikologicheskogo analiza. [Authentication study of the preparation 'Avastin' by means of chemical-toxicological analysis]. Sudebno-meditsinskaia ekspertiza, 62(5), 47-53. https://doi.org/10.17116/sudmed20196205147
Mesonzhnik, N V, et al. "Issledovanie podlinnosti preparata 'Avastin' metodami khimiko-toksikologicheskogo analiza." [Authentication study of the preparation 'Avastin' by means of chemical-toxicological analysis]. Sudebno-meditsinskaia ekspertiza vol. 62,5 (2019): 47-53. doi: https://doi.org/10.17116/sudmed20196205147
Mesonzhnik NV, Kuznetsov RM, Postnikov PV, Bochkareva NL, Markin PA, Kurynina KO, Appolonova SA. Issledovanie podlinnosti preparata 'Avastin' metodami khimiko-toksikologicheskogo analiza. [Authentication study of the preparation 'Avastin' by means of chemical-toxicological analysis]. Sud Med Ekspert. 2019;62(5):47-53. doi: 10.17116/sudmed20196205147. Russian. PMID: 31626195.
Copy Download .nbib Format: NLM
Limitations of the quality range approach in analytical similarity assessment: Effect of mean shift and relative variability.

Journal of pharmaceutical and biomedical analysis

Oliva A, Llabrés M.
PMID: 33730613
J Pharm Biomed Anal. 2021 May 10;198:114017. doi: 10.1016/j.jpba.2021.114017. Epub 2021 Mar 10.

Recently in 2019, the United States Food and Drug Administration (FDA) circulated a new draft guidance for comparative analytical assessment. They suggest the use of quality range (QR) methods. In this article, selection of the k value, and the...

Cite
Oliva A, Llabrés M. Limitations of the quality range approach in analytical similarity assessment: Effect of mean shift and relative variability. J Pharm Biomed Anal. 2021;198:114017doi: 10.1016/j.jpba.2021.114017.
Oliva, A., & Llabrés, M. (2021). Limitations of the quality range approach in analytical similarity assessment: Effect of mean shift and relative variability. Journal of pharmaceutical and biomedical analysis, 198114017. https://doi.org/10.1016/j.jpba.2021.114017
Oliva, Alexis, and Llabrés, Matías. "Limitations of the quality range approach in analytical similarity assessment: Effect of mean shift and relative variability." Journal of pharmaceutical and biomedical analysis vol. 198 (2021): 114017. doi: https://doi.org/10.1016/j.jpba.2021.114017
Oliva A, Llabrés M. Limitations of the quality range approach in analytical similarity assessment: Effect of mean shift and relative variability. J Pharm Biomed Anal. 2021 May 10;198:114017. doi: 10.1016/j.jpba.2021.114017. Epub 2021 Mar 10. PMID: 33730613.
Copy Download .nbib Format: NLM
Myopic choroidal neovascularization: To load or not to load.

Clinical & experimental ophthalmology

Cornish EE, Gillies MC.
PMID: 30892793
Clin Exp Ophthalmol. 2019 Mar;47(2):161-162. doi: 10.1111/ceo.13473.

No abstract available.

Cite
Cornish EE, Gillies MC. Myopic choroidal neovascularization: To load or not to load. Clin Exp Ophthalmol. 2019;47(2):161-162doi: 10.1111/ceo.13473.
Cornish, E. E., & Gillies, M. C. (2019). Myopic choroidal neovascularization: To load or not to load. Clinical & experimental ophthalmology, 47(2), 161-162. https://doi.org/10.1111/ceo.13473
Cornish, Elisa E, and Gillies, Mark C. "Myopic choroidal neovascularization: To load or not to load." Clinical & experimental ophthalmology vol. 47,2 (2019): 161-162. doi: https://doi.org/10.1111/ceo.13473
Cornish EE, Gillies MC. Myopic choroidal neovascularization: To load or not to load. Clin Exp Ophthalmol. 2019 Mar;47(2):161-162. doi: 10.1111/ceo.13473. PMID: 30892793.
Copy Download .nbib Format: NLM
The Role of Maintenance Therapy in Metastatic Colorectal Cancer.

JAMA oncology

Wang ZX, Liang F, Xu RH.
PMID: 32297912
JAMA Oncol. 2020 Jun 01;6(6):937. doi: 10.1001/jamaoncol.2020.0580.

No abstract available.

Cite
Wang ZX, Liang F, Xu RH. The Role of Maintenance Therapy in Metastatic Colorectal Cancer. JAMA Oncol. 2020;6(6):937doi: 10.1001/jamaoncol.2020.0580.
Wang, Z. X., Liang, F., & Xu, R. H. (2020). The Role of Maintenance Therapy in Metastatic Colorectal Cancer. JAMA oncology, 6(6), 937. https://doi.org/10.1001/jamaoncol.2020.0580
Wang, Zi-Xian, et al. "The Role of Maintenance Therapy in Metastatic Colorectal Cancer." JAMA oncology vol. 6,6 (2020): 937. doi: https://doi.org/10.1001/jamaoncol.2020.0580
Wang ZX, Liang F, Xu RH. The Role of Maintenance Therapy in Metastatic Colorectal Cancer. JAMA Oncol. 2020 Jun 01;6(6):937. doi: 10.1001/jamaoncol.2020.0580. PMID: 32297912.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 14 entries